Curated News
By: NewsRamp Editorial Staff
November 03, 2026
Helus Pharma CEO to Present at Guggenheim Healthcare Conference
TLDR
- Helus Pharma CEO Michael Halstead's Guggenheim fireside chat offers investors a strategic edge on its FDA-designated HLP003 for depression.
- Helus Pharma CEO Michael Halstead will present at the Guggenheim Healthcare Innovation Conference on Nov. 9, 2026, with a live webcast and replay.
- Helus Pharma's serotonergic agonists aim to provide durable mental health improvements for people suffering from depression and anxiety.
- Helus Pharma, known as Cybin Inc., develops proprietary NSAs, and its HLP003 holds FDA Breakthrough Therapy Designation for major depressive disorder.
Impact - Why it Matters
This news matters because Helus Pharma's participation in the Guggenheim Healthcare Innovation Conference provides a platform for the company to share its progress on novel serotonergic agonists (NSAs) for mental health treatment. With HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder, Helus Pharma is advancing a pipeline that could offer new therapeutic options for patients who have not responded to existing treatments. The Breakthrough Therapy Designation for HLP003 underscores the potential of NSAs to address significant unmet needs in mental health care. Investors and industry stakeholders will be watching the fireside chat for insights into the company's clinical strategy and timelines, which could impact the company's valuation and the broader psychedelic medicine sector.
Summary
Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health treatment, announced that CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston. The presentation is scheduled for Monday, Nov. 9, 2026, at 3 p.m. ET. The fireside chat will be webcast live, with registration available through the conference webcast platform, and a replay will be available on the Events & Presentations page of the company’s investor relations website.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through NSAs that provide durable improvements in mental health. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. Helus Pharma(TM) is a trademark of Cybin Corp.
The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP. The announcement was disseminated by InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication for private and public companies and the investment community. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma CEO to Present at Guggenheim Healthcare Conference
